<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05093335</url>
  </required_header>
  <id_info>
    <org_study_id>21-356</org_study_id>
    <nct_id>NCT05093335</nct_id>
  </id_info>
  <brief_title>In-Human CXCR4 Imaging of Blood Cancers Using [68Ga]-Pentixafor-PET</brief_title>
  <official_title>In-human CXCR4 Imaging of Blood Cancers Using [68Ga]-Pentixafor-PET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor&#xD;
      with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS),&#xD;
      smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This protocol is a pilot protocol.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor standard uptake value (SUV)</measure>
    <time_frame>1 year</time_frame>
    <description>Means and 95% confidence intervals for [68Ga]-Pentixafor standardized uptake values (SUV) and tumor-to-background ratios (TBR) of tumors will be recorded. Uptake will be measured in tumors.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>[68Ga]-Pentixafor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An intravenous bolus of 4.1 mCi (150 MBq) ± 10% of [68Ga]-Pentixafor will be injected in all participants that will be imaged on a hybrid PET/CT device. Any of the following factors may determine if imaging cannot be performed: tolerance/compliance in the PET/CT scanner; dose availability; dose quality control; availability of the PET/CT scanner or availability of study personnel. [68Ga]-Pentixafor uptake dynamics / pharmacokinetics will be evaluated by PET/CT performed with a low-dose CT component used for PET attenuation correction (1-2 mSv). [68Ga]-Pentixafor-PET/CT scan duration will be approximately 1.5 hours. Some patients will have two scans.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[68Ga]-Pentixafor</intervention_name>
    <description>An intravenous bolus of 4.1 mCi (150 MBq) ± 10% of [68Ga]-Pentixafor will be injected in all participants.</description>
    <arm_group_label>[68Ga]-Pentixafor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Twenty patients with histologically proven treatment-naïve, therapy-refractory or relapsed&#xD;
        blood cancers meeting the below criteria will be included:&#xD;
&#xD;
          -  Indolent B- or T-cell Non-Hodgkin lymphoma (including cutaneous lymphomas) and&#xD;
             measurable disease according to Lugano criteria&#xD;
&#xD;
          -  MGUS/SMM according to IMWG definitions&#xD;
&#xD;
          -  Age ≥18&#xD;
&#xD;
          -  Negative serum pregnancy test for female volunteers of childbearing age and potential&#xD;
             (as defined by MSKCC Standards &amp; Guidelines) from assays obtained &lt;2 weeks prior to&#xD;
             study enrollment/intervention; or negative urine pregnancy test performed on the day&#xD;
             of intervention&#xD;
&#xD;
          -  MSKCC patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Breast-feeding&#xD;
&#xD;
          -  History of renal functional disorders (chronic kidney disease with eGFR&lt;30)&#xD;
&#xD;
          -  Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)&#xD;
&#xD;
          -  CNS lymphoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marius Mayerhoefer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marius Mayerhoefer, MD, PhD</last_name>
    <phone>646-961-5030</phone>
    <email>mayerhom@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heiko Schoder, MD</last_name>
    <phone>212-639-2079</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marius Mayerhoefer, MD, PhD</last_name>
      <phone>646-961-5030</phone>
    </contact>
    <contact_backup>
      <last_name>Heiko Schoder, MD</last_name>
      <phone>212-639-2079</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>[68Ga]-Pentixafor</keyword>
  <keyword>PET/CT scan</keyword>
  <keyword>In-human CXCR4 Imaging</keyword>
  <keyword>21-356</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

